POET Technologies (NASDAQ: POET) is ripping higher this morning after responding swiftly to a short-seller report that alleged it’s an “obvious stock promote” designed to enrich insiders while leaving retail investors with a “tax nightmare.” According to Wolfpack Research – the firm behind the hit piece – POET’s financial structure will trigger severe IRS penalties… Continue reading Why POET stock is soaring despite short-seller report?
stocktrader
Why Nvidia stock slipped below $200 on Monday
Nvidia shares pulled back below the $200 mark in early Monday trading, giving up recent gains as competitive pressures in the artificial intelligence chip sector showed no signs of easing. The stock fell 1.5% to $198.51, declining more steeply than major benchmarks. The S&P 500 was down 0.4%, the Nasdaq Composite shed 0.7%, and the… Continue reading Why Nvidia stock slipped below $200 on Monday
ChatGPT outage hits globally as OpenAI probes access issues
OpenAI faced a widespread outage affecting its flagship chatbot ChatGPT and coding tool Codex, disrupting users across multiple regions even as the company announced a record-breaking funding round that underscores investor confidence in artificial intelligence. The outage began around 10:05 a.m. ET, with a sharp spike in user complaints logged on Downdetector. Reports indicated that… Continue reading ChatGPT outage hits globally as OpenAI probes access issues
Google news sends Marvell stock to a record high
Marvell Technology (NASDAQ: MRVL) opened comfortably in “green” this morning after reports surfaced that it’s in active discussions to co-develop two new custom AI chips for Alphabet Inc. The Wilmington-headquartered firm will reportedly help Google design both specialized memory processing unit (MPU) and an inference-optimized Tensor Processing Unit (TPU). Marvell stock has been a lucrative… Continue reading Google news sends Marvell stock to a record high
Tesla stock slips 2% on Monday after last week’s rally: here’s why
Shares of Tesla declined more than 2% on Monday, underperforming broader US equity markets. The move came as investors turned cautious ahead of the company’s first-quarter earnings report and awaited updates on its artificial intelligence strategy. The stock’s decline came even as the Dow Jones Industrial Average slipped just 0.1%, while the S&P 500 fell… Continue reading Tesla stock slips 2% on Monday after last week’s rally: here’s why
Adobe stock jumps as AI agent push aims to fend off rising competition
Shares of Adobe rose on Monday after the company unveiled a new artificial intelligence agent platform aimed at strengthening its position in an increasingly competitive software landscape. The stock climbed about 2.49% to $250.53, outperforming a broader market decline that saw the S&P 500 fall 0.14% and the Nasdaq Composite drop 0.34%. Despite the gain,… Continue reading Adobe stock jumps as AI agent push aims to fend off rising competition
Dow Jones flat as Iran tensions rise; S&P 500, Nasdaq slip
Wall Street’s main indexes opened lower on Monday, as renewed tensions between the US and Iran weighed on investor sentiment following a record-setting rally last week. The Dow Jones Industrial Average gained 28 points, while the S&P 500 slipped 0.17% and the Nasdaq-100 declined about 0.13%. The pullback comes after a strong run that pushed… Continue reading Dow Jones flat as Iran tensions rise; S&P 500, Nasdaq slip
From record inflows to 12% drawdown, what went wrong for Europe?
Three months ago, European investors were pouring money into the continent’s stock markets at a record pace, betting that years of underperformance were finally coming to an end. The euro was strong, defence stocks were surging, and the valuation gap with the US was too wide to ignore. Then came the Iran war, the closure… Continue reading From record inflows to 12% drawdown, what went wrong for Europe?
Eli Lilly to acquire Kelonia in $7 billion cancer therapy push
Eli Lilly said on Monday it will acquire privately held Kelonia Therapeutics in a deal worth up to $7 billion, as the drugmaker deepens its presence in next-generation cancer treatments. The agreement includes an upfront payment of $3.25 billion, with additional payouts tied to clinical, regulatory and commercial milestones. The transaction is expected to close… Continue reading Eli Lilly to acquire Kelonia in $7 billion cancer therapy push
